UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C.  20549

                           FORM 10-QSB


[X]   QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
      ACT OF 1934

      For quarterly period ended June 30, 2004

[ ]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934


      Commission File No.  000-30991


             SKINOVATION PHARMACEUTICAL INCORPORATED
   (Name of small business issuer as specified in its charter)


                NEVADA                       87-0458170
        (State of incorporation) (I.R.S. Employer Identification No.)

                      2157 S. Lincoln Street
                    Salt Lake City, Utah 84106
                          (801) 323-2395
  (Address and telephone number of principal executive offices)

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes [X]   No [ ]

As of July 13, 2004 the issuer had a total of 708,000 shares of common stock
issued and outstanding.

Transitional small business disclosure format:  Yes [ ]  No [X]


<PAGE>


                        TABLE OF CONTENTS

                  PART I: FINANCIAL INFORMATION

Item 1.  Financial Statements............................................... 2

Item 2.  Plan of Operation...................................................8

Item 3.  Controls and Procedures.............................................8

                    PART II: OTHER INFORMATION

Item 6.  Exhibits and Reports on Form 8-K....................................9

Signatures...................................................................9





                 PART I:   FINANCIAL INFORMATION


ITEM 1. FINANCIAL STATEMENTS

The financial information set forth below with respect to our statements of
operations for the three and six month periods ended June 30, 2004 and 2003 is
unaudited.  This financial information, in the opinion of management, includes
all adjustments consisting of normal recurring entries necessary for the fair
presentation of such data.  The results of operations for the six month period
ended June 30, 2004 are not necessarily indicative of results to be expected
for any subsequent period.



                                2
<PAGE>







             Skinovation Pharmaceutical Incorporated

                       Financial Statements

                          June 30, 2004







                                3

<PAGE>



             Skinovation Pharmaceutical Incorporated
                  (A Development Stage Company)
                          Balance Sheets


                              ASSETS

                                                     June 30,    December 31,
                                                       2004         2003
                                                  ------------- -------------
                                                   (Unaudited)
CURRENT ASSETS
   Cash                                           $      3,694  $          -
                                                  ------------- -------------

  TOTAL ASSETS                                    $      3,694  $          -
                                                  ============= =============


               LIABILITIES AND STOCKHOLDER' EQUITY

CURRENT LIABILITIES
  Accounts Payable - Related party                $     33,776  $     33,776
  Advances Payable                                       5,000             -
                                                  ------------- -------------

  Total Liabilities                                     38,776        33,776
                                                  ------------- -------------
STOCKHOLDERS' EQUITY

  Common Stock, $.001 par value; 50,000,000
    shares authorized; 708,000 shares
    issued and outstanding                                 708           708

  Additional Paid in Capital                            25,148        25,148

  Deficit Accumulated During the Development Stage     (60,938)      (59,632)
                                                  ------------- -------------

  Total Stockholders' Equity                           (35,082)      (33,776)
                                                  ------------- -------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY      $      3,694  $          -
                                                  ============= =============









                                4



<PAGE>



             Skinovation Pharmaceutical Incorporated
                  (A Development Stage Company)
                     Statement of Operations
                           (Unaudited)


<TABLE>
<CAPTION>
                                                                                        From
                                                                                        Inception on
                            For the three  For the three  For the six    For the six    January 15,
                            months ended   months ended   months ended   months ended   1988
                            June 30,       June 30,       June 30,       June 30,       to June 30,
                            2004           2003           2004           2003           2004
                            -------------- -------------- -------------- -------------- --------------

                         <c>            <c>            <c>            <c>            <c>
REVENUES                    $           -  $           -  $           -  $           -  $      27,937
                            -------------- -------------- -------------- -------------- --------------
EXPENSES
  General & Administrative          1,306              -          1,159              -        125,950
                            -------------- -------------- -------------- -------------- --------------

    TOTAL EXPENSES                  1,306              -          1,159              -        125,950
                            -------------- -------------- -------------- -------------- --------------
NET LOSS BEFORE
 DISCONTINUED OPERATIONS           (1,306)             -         (1,159)             -        (98,013)

GAIN ON DISPOSAL
 OF OPERATIONS                          -              -              -              -         37,075
                            -------------- -------------- -------------- -------------- --------------

NET INCOME (LOSS)           $      (1,306) $           -  $      (1,159) $           -  $     (60,938)
                            ============== ============== ============== ============== ==============

NET LOSS PER SHARE          $           -  $           -  $           -  $           -  $       (0.16)
                            ============== ============== ============== ============== ==============
WEIGHTED AVERAGE SHARES
 OUTSTANDING                      708,000        708,000        708,000        708,000        369,006
                            ============== ============== ============== ============== ==============





                                        5
</TABLE>
<PAGE>
<TABLE>
<CAPTION>


                  Skinovation Pharmaceutical Incorporated
                       (A Development Stage Company)
                          Statement of Cash Flows
                                (Unaudited)


                                                                               From
                                                                               Inception on
                                                                               January 15,
                                                    For the six months ended   1988
                                                            June 30,           Through
                                                 ----------------------------- June 30,
                                                       2004          2003      2004
                                                 -------------- -------------- --------------

                                              <c>            <c>            <c>
Cash Flows from Operating Activities
  Net Loss                                       $      (1,306) $           -  $     (60,938)
  Less  Non-cash Items:
  Shares issued for services                                 -              -         10,433
  Shares issued for debt payment                             -              -          1,424
  Increase in accounts payable                               -              -         33,776
  Loss on disposal of PP&E                                   -              -          5,263
                                                 -------------- -------------- --------------

  Net Cash Provided (Used) by Operating Activities      (1,306)             -        (10,042)
                                                 -------------- -------------- --------------
Cash Flows from Investing Activities
  Cash paid for PP&E                                         -              -         (5,264)
                                                 -------------- -------------- --------------

  Net Cash Provided (Used) by Investing Activities           -              -         (5,264)
                                                 -------------- -------------- --------------
Cash Flows from Financing Activities
  Cash received from advances                            5,000              -          5,000
  Cash paid for offering costs                               -              -         (7,000)
  Common stock issued for cash                               -              -         21,000
                                                 -------------- -------------- --------------

  Net Cash Provided (Used) by Financing Activities       5,000              -         19,000
                                                 -------------- -------------- --------------

Increase (Decrease) in Cash                              3,694              -          3,694

Cash and Cash Equivalents at Beginning of Period             -              -              -
                                                 -------------- -------------- --------------

Cash and Cash Equivalents at End of Period       $       3,694  $           -  $       3,694
                                                 ============== ============== ==============

Supplemental Cash Flow Information:

  Stock issued for debt payment                  $           -  $           -  $       1,424
  Stock issued for services                      $           -  $           -  $      10,433

  Cash Paid For:
    Interest                                     $           -  $           -  $           -
    Income Taxes                                 $           -  $           -  $           -



                                     6


</TABLE>
<PAGE>




             Skinovation Pharmaceutical Incorporated
                Notes to the Financial Statements
                          June 30, 2004


GENERAL

Skinovation Pharmaceutical Incorporated (the Company) has elected to omit
substantially all footnotes to the financial statements for the six months
ended June 30, 2004 since there have been no material changes (other than
indicated in other footnotes) to the information previously reported by the
Company in their Annual Report filed on the Form 10-KSB for the twelve months
ended December 31, 2003.

UNAUDITED INFORMATION

The information furnished herein was taken from the books and records of the
Company without audit.  However, such information reflects all adjustments
which are, in the opinion of management, necessary to properly reflect the
results of the interim period presented.  The information presented is not
necessarily indicative of the results from operations expected for the full
fiscal year.

                                7
<PAGE>


In this report references to "Skinovation," "we," "us," and "our" refer to
Skinovation Pharmaceutical Incorporated.

        SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

The Securities and Exchange Commission ("SEC") encourages companies to
disclose forward-looking information so that investors can better understand
future prospects and make informed investment decisions.  This report contains
these types of statements.  Words such as "may," "will," "expect," "believe,"
"anticipate," "estimate," "project," or "continue" or comparable terminology
used in connection with any discussion of future operating results or
financial performance identify forward-looking statements.  You are cautioned
not to place undue reliance on the forward-looking statements, which speak
only as of the date of this report.  All forward-looking statements reflect
our present expectation of future events and are subject to a number of
important factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.

ITEM 2.  PLAN OF OPERATION

During the next twelve months our management intends to actively seek an
operating company to acquire or merge with which may provide operating
revenue.  Based on current economic and regulatory conditions, management
believes that it is possible, if not probable, for a company like ours,
without many assets or liabilities, to negotiate a merger or acquisition with
a viable private company.  The opportunity arises principally because of the
high legal and accounting fees and the length of time associated with the
process of "going public."  However, should a merger or acquisition prove
unsuccessful, it is possible that we may decide not to pursue further
acquisition activities and management may abandon its activities and our
shares would become worthless.

As of the date of this filing, we have not identified any assets or business
opportunities for acquisition.  Potential investors must recognize that
because of limited capital available for investigation of business
opportunities and management's limited experience in business analysis, we may
not discover or adequately evaluate adverse facts about any business
opportunity to be acquired.  All risks inherent in new and inexperienced
enterprises are inherent in our plan.

It is emphasized that our management may effect transactions having a
potentially adverse impact upon our shareholders pursuant to the authority and
discretion of our management to complete acquisitions without submitting any
proposal to the stockholders for their consideration.

As of June 30, 2004 we had $3,694 cash on hand and total current liabilities
of $38,776.  We currently cannot satisfy our cash requirements for our
operations.  The majority of our operating expenses are related to our
reporting obligations under the Exchange Act.  These expenses include legal,
accounting and professional services required to prepare our reports and the
costs of filing the reports with the SEC.  We are unable to pay cash for these
services and have relied on related parties to pay for these costs on our
behalf.  These parties have not entered into written agreements guaranteeing
advances and, therefore, they are not obligated to provide funds in the
future.  However, management anticipates that these parties will continue to
pay for these costs on our behalf during the next twelve months.
Historically, we have paid for these advances by converting the debt into
common stock.

ITEM 3.  CONTROLS AND PROCEDURES

Our President, who acts in the capacity of principal executive officer and
principal financial officer, has concluded that the disclosures related to the
effectiveness of our disclosure controls and procedures and our internal
control over financial reporting made in our annual report on Form 10-KSB,
filed March 23, 2004, remain accurate.


                                8
<PAGE>


                   PART II:  OTHER INFORMATION

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

Part I  Exhibits

31.1    Principal Executive Officer Certification
31.2    Principal Financial Officer Certification
32.1    Section 1350 Certification

Part II Exhibits

3.1     Articles of Incorporation as amended  (Incorporated by reference to
        exhibit 3.1 of the Form 10-KSB, filed March 29, 2002)
3.2     Bylaws of Skinovation (Incorporated by reference to exhibit 3.3 of the
        Form-SB, filed July 11, 2000)

Reports on Form 8-K

None.


                            SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


                                    Skinovation Pharmaceutical Incorporated


                                        /S/ John W. Peters
Date: August 3, 2004                By: ____________________________________
                                        John W. Peters
                                        President, Principal Executive and
                                        Financial Officer, and Director


                                9